Login to Your Account



Other News To Note


Wednesday, March 21, 2012
• Halo Therapeutics LLC, of Newton, Mass., said the independent TREAT-NMD Advisory Committee on Therapeutics offered a favorable review of HT-100, Halo's drug candidate for Duchenne's muscular dystrophy, endorsing the company's plan to move the drug candidate to a clinical trial. HT-100, a formulation of halofuginone, is an orally available small-molecule drug candidate designed to reduce fibrosis and promote healthy muscle fiber regeneration.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription